• Arvinas (NASDAQ:ARVN) announced that the company and its partner, Pfizer (NYSE:PFE), decided to postpone the projected completion date for their jointly conducted Phase 3 trial for the breast cancer therapy vepdegestrant.
• Accordingly, the VERITAC-2 monotherapy clinical trial, designed to test the protein degrader in patients with metastatic breast cancer, is expected to be completed in January, a delayed timeline from the companies’ previous projection for November 2024.
• The duo has made the decision based on the current trial status, including data on enrollments and blinded event rates. Given the revised completion date, Pfizer (NYSE:PFE) and Arvinas (NASDAQ:ARVN) expect to share topline data from VERITAC-2 in Q1 2025.
• With its Q3 2024 results, New Haven, Connecticut-based Arvinas (ARVN) said VERITAC-2, which has completed enrollments in Q4, is anticipated to generate topline data this year or Q1 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.